Wall Street Signals: Can B Corp Announces First Quarter 2021 Results

Can B Corp Announces First Quarter 2021 Results




- Strengthened Balance Sheet with $1.7 Million Cash Balance
- Strong Gross Margin of 75%

Can B Corp. (OTCQB:CANB) ("Can B" or the "Company") a diversified health and wellness company, announced today operating and financial results for the three months ended March 31, 2021.

Marco Alfonsi, Can B's Chief Executive Officer, commented, "While we experienced a decline in our revenue due to Covid-19's negative impact on markets we serve in elective surgeries and lost clients due to business closings of certain distributors, we have taken the time to maintain and strengthen our vertically integrated platform. As an integrated health & Wellness company providing the highest quality cannabidiol (CBD) and traditional wellness products, our business pipeline remains strong for both our own branded lines and our private label contract manufacturing. Additionally, we are in several ongoing discussions with potential corporate opportunities and strategic partnerships and acquisitions that would accelerate our growth."

Key Recent Highlights:

  • Tripled production with the installation of new high-speed equipment to expand production at its Pure Health Products facility in Lacey, Washington

  • Launched ImmuneX2 in collaboration with Dr. Karl Zarse, a super immune boosting twice a day AM/PM supplement

  • Acquired assets from a leading-edge hemp technology group to add expertise in pharmacokinetics for the confluence of science, nature, and culture

  • Cash balance of $1.7 million, as of April 2021

Closed on the acquisition of assets and talent from a hemp derivative development and manufacturing group.


Financial Results for the Three Months Ended March 31, 2021:

Revenue for the three months ended March 31, 2021, was $306,940, a decrease of $262,767 or 46%, compared to $569,707 for the three months ended March 31, 2020. The decrease was due to the impact of the COVID-19 outbreak which resulted in the termination of elective surgeries which is the Company's primary medical device revenue. In addition, certain distributors lost clients due to business closings which had an additional impact on the Company's overall revenue activity.

Gross profit for the three months ended March 31, 2021, was $230,145, resulting in a gross margin of 75.0%, compared to $448,158 and 78.7% for the three months ended March 31, 2020. Absolute gross profit decreased due to a decrease in sales because of the Covid-19 pandemic.

A recently shaped completely possessed auxiliary, Botanical Biotech LLC ("BB"), will be the new home for Florida-based examination and improvement research center and extraction office for the Company. BB will zero in on creating and carrying out new pharmacokinetics innovation and banding together with worldwide and arising brands to make imaginative items and arrangements that are situated for maintainability and wellbeing and are socially determined.

Signed a definitive agreement to acquire the assets of Imbibe Health Solutions LLC ("Imbibe"), a developer and marketer of CBD and related products. Imbibe has developed several CBD health and wellness products including topical salves, bath soaks, massage oils, and energy and dietary supplements. Can B be putting Imbibe into one of its current inactive wholly-owned subsidiaries and will be renaming that subsidiary to reflect the products and culture that comes with the Imbibe acquisition.

Operating expenses for the three months ended March 31, 2021 were $2,022,679, an increase of $462,528 or 30%, compared to $1,560,151 for the three months ended March 31, 2020. This increase was a direct result of professional fees incurred and attributable to the Company's asset acquisitions and Regulation A offering.

Operating loss for the three months ended March 31, 2021 was $1,792,534, an increase of $680,541 or 62%, compared to $1,111,993 for the three months ended March 31, 2020.

Net loss for the three months ended March 31, 2021 was $2,179,882, an increase of $1,045,775 or 92%, compared to $1,134,107 for the three months ended March 31, 2020. The resulting EPS loss for the three months ended December 31, 2021, was a ($0.24), as compared to an EPS loss of ($0.33) for the three months ended March 31, 2020. The increase in net loss was due to the $462,528 increase in total operating expenses coupled with the $366,059 increase in other expense - net, the $825 decrease in provision for income taxes, and the $181,987 decrease in gross profit.

About Can B Corp.

Can B Corp. (OTCQB: CANB) is a Health & Wellness company providing the highest quality cannabidiol (CBD) products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil, and Duramed. Can B utilize multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct? The Company has launched Super Foods, a line of nutritional supplements. Can B Corp. own and operates an R&D and production facility in Lacey, WA, and Green Grow Farms, licensed hemp to grow and cultivate in New York? To learn more about Can B Corp. and our comprehensive line of high-quality CBD products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.

For more information about Can B Corp., please visit: CanBCorp.com

Twitter @CanBCorp
Instagram @canbcorp
Facebook @ Can B Corp
Youtube